WO2022091442A1 - ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物 - Google Patents

ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物 Download PDF

Info

Publication number
WO2022091442A1
WO2022091442A1 PCT/JP2021/006418 JP2021006418W WO2022091442A1 WO 2022091442 A1 WO2022091442 A1 WO 2022091442A1 JP 2021006418 W JP2021006418 W JP 2021006418W WO 2022091442 A1 WO2022091442 A1 WO 2022091442A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
vaginal
compound
nonionic surfactant
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/006418
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
博 小野木
哲夫 山口
克彦 佐藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KinoPharma Inc
Original Assignee
KinoPharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2022558836A priority Critical patent/JP7606239B2/ja
Priority to US18/033,584 priority patent/US20230398107A1/en
Priority to ES21885567T priority patent/ES3045576T3/es
Priority to CA3199945A priority patent/CA3199945A1/en
Priority to KR1020237014225A priority patent/KR20230098175A/ko
Priority to CN202180045812.6A priority patent/CN115734782A/zh
Application filed by KinoPharma Inc filed Critical KinoPharma Inc
Priority to EP21885567.4A priority patent/EP4238565B1/en
Priority to PL21885567.4T priority patent/PL4238565T3/pl
Publication of WO2022091442A1 publication Critical patent/WO2022091442A1/ja
Priority to ZA2023/04812A priority patent/ZA202304812B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a pharmaceutical composition for the prevention and / or treatment of viral vaginal peripheral diseases.
  • Cervical cancer is one of the most common malignant lesions in women, and its treatment and early detection are desired all over the world. Cervical cancer accounts for about 70% of uterine cancers and about 20% of all obstetrics and gynecology cancers, and is an important disease target. Cervical cancer affects 500,000 people worldwide and about 10,000 people in Japan every year, and the number of patients is increasing.
  • cervical cancer is mostly caused by human papillomavirus (HPV) infection.
  • HPV human papillomavirus
  • HPV16 14 types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) are called high-risk types, especially HPV16.
  • HPV16 14 types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) are called high-risk types, especially HPV16.
  • HPV16 high-risk types
  • HPV is a common virus that infects both men and women, and is often transmitted by sexual intercourse. However, even when infected with high-risk HPV, in many cases (about 90%), it disappears spontaneously by the host's immunity. On the other hand, about 10% of people have persistent HPV infection, and some of those who do not heal spontaneously have cervical cancer over a period of several to 10 years after undergoing a precancerous lesion called dysplasia. Progress to.
  • Cervical dysplasia is a pre-stage of cervical cancer (precancerous lesion) and is also called cervical intraepithelial neoplasia (CIN).
  • Cervical dysplasia is classified into three types, mild dysplasia (CIN1), moderate dysplasia (CIN2), and severe dysplasia / carcinoma in situ (CIN3), depending on the degree of the lesion.
  • cervical dysplasia is classified into LSIL (mild abnormality) and HSIL (moderate to severe abnormality) in the Bethesda classification by vaginal cytopathology.
  • Cervical dysplasia is a disease that often does not show subjective symptoms and is often detected by cervical cancer screening (cytopathology), and early treatment is important.
  • the detection rate of high-risk HPV is about 60% for mild dysplasia of the squamous epithelial system, about 85% for moderate dysplasia, about 90% for severe dysplasia / carcinoma in situ, and about 100 for squamous cell carcinoma. There is a report of%.
  • Cytopathology is the primary screening in cervical cancer screening, and if abnormalities are found in the cytopathology, colposcopy and histology are performed as the secondary screening (detailed examination).
  • Current diagnosis is that mild dysplasia (CIN1) and moderate dysplasia (CIN2) are often followed up rather than treated immediately. The reason is that about half of the patients often heal (disappear) spontaneously without treatment, while the current surgical treatments are extremely invasive and burdensome to the patients.
  • CIN3 severe dysplasia / carcinoma in situ
  • CIN2 condition of CIN2 persists for a long period of time.
  • a typical surgical treatment is cervical conization, in which the cervix (entrance portion) is excised in a conical shape.
  • This surgery may be performed not only for CIN3 but also for microinfiltrating squamous cell carcinoma (stage Ia1). Especially for patients who wish to become pregnant (uterine preservation), this surgery is the first choice, but for patients who do not need uterine preservation, total hysterectomy may be selected.
  • Condyloma acuminata is one of the sexually transmitted diseases caused by the human papillomavirus, and it infects both men and women, and it is reported that dozens of people are infected per 100,000 in Japan. In women, it affects the vagina, vaginal vestibule, large and small labia, cervix, anus and periphery. Even if it develops, it often heals spontaneously.
  • the human papillomaviruses that cause condyloma acuminata are mainly HPV 6 and 11, which are types of viruses with a low risk of carcinogenesis. However, malignant viruses such as HPV 16 and 18 that have a high risk of developing cervical cancer may be infected at the same time. In women, when condyloma acuminata develops in the vulva, it may be infected with a malignant type of HPV that causes uterine cancer and the like.
  • Genital herpes is infected with the herpes simplex virus and develops in or around the genitals. In women, lesions are found in the vulva, vagina and cervix. Genital herpes can be an initial infection with an externally invading virus or a reactivation of the virus lurking in the sacral ganglion.
  • aniline derivatives such as N- [5-fluoro-2- (1-piperidinyl) phenyl] isonicotinthioamide, which is a CDK9 inhibitor, can be used as an antiviral agent that suppresses virus production.
  • aniline derivatives such as N- [5-fluoro-2- (1-piperidinyl) phenyl] isonicotinthioamide, which is a CDK9 inhibitor, can be used as an antiviral agent that suppresses virus production.
  • the surfactant has adhesiveness and adhesiveness and lowers the fluidity of powders and granules, there is a problem that the blending amount is limited when it is used for the preparation of pharmaceutical preparations such as tablets. be.
  • a vaginal insertion agent capable of containing the above-mentioned compound, which is a poorly water-soluble drug, in a therapeutically effective amount and providing sufficient absorbability into a living body.
  • An object of the present invention is to provide a pharmaceutical composition for the prevention and / or treatment of viral intravaginal or peripheral vaginal diseases.
  • the present invention provides a pharmaceutical composition for preventing and / or treating cervical cancer, cervical intraepithelial neoplasia, or condyloma acuminata, which is a disease that develops in the peripheral vagina caused by human papillomavirus. That is.
  • vaginal tablets which are preparations containing the following compounds having antiviral activity against human papillomavirus and herpes simplex and exhibit good compound stability, elution or bioabsorbability. We succeeded in completing the present invention.
  • the present invention includes: [1] The following general formula (I)
  • [W represents S or O in the formula] Diseases caused in the vagina or around the vagina by a pathogenic virus containing a compound selected from the group consisting of an aniline derivative represented by the above, a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient.
  • a pharmaceutical composition for treating or preventing The pharmaceutical composition comprises nuclear particles containing the compound, needle-like and / or substantially columnar-shaped crystalline cellulose, a pharmaceutically acceptable substantially spherical additive, and a nonionic surfactant, and the nuclear particles.
  • a pharmaceutical composition in the form of a vaginal insert eg, vaginal tablet, vaginal capsule, or vaginal suppository
  • the pharmaceutical composition wherein the nuclear particles have voids between the crystalline cellulose and the additive.
  • the compound has the following formula (Ia).
  • the nonionic surfactant is contained in an amount of 1.5 times or less that of the compound.
  • the nonionic surfactant is contained in any one of the above [1] to [5] in an amount of 1.5% by weight or more and less than 10% by weight based on the total amount of the pharmaceutical composition.
  • the nonionic surfactant is contained in an amount of 1.5% by weight or more and less than 10% by weight based on the total amount of the pharmaceutical composition, and 1.5 times or less the amount of the compound [1]. ]
  • the diseases are diseases diagnosed as LSIL, ASC-US, ASC-H, or HSIL according to the Bethesda classification, mild dysplastic cervical intraepithelial neoplasia (CIN1), and moderate dysplastic cervical cervix.
  • CIN2 intraepithelial neoplasia
  • CIN3 highly dysplastic cervical intraepithelial neoplasia
  • the pharmaceutical composition according to any one of the above [1] to [9] wherein the disease is condyloma acuminata.
  • the vaginal insert is in the form of a vaginal tablet.
  • [W represents S or O in the formula] Diseases caused in the vagina or around the vagina by a pathogenic virus containing a compound selected from the group consisting of an aniline derivative represented by the above, a pharmaceutically acceptable salt thereof, or a hydrate thereof as an active ingredient.
  • a method for producing a pharmaceutical composition for treating or preventing a virus which comprises the following steps: (A) A step of mixing a nuclear particle raw material containing needle-shaped and / or substantially columnar crystalline cellulose and a pharmaceutically acceptable substantially spherical additive to obtain a nuclear particle mixture. (B) A step of dissolving or suspending the compound in a mixture of a nonionic surfactant and a solvent to obtain a mixed solution.
  • the compound, the acicular and / or substantially columnar crystalline cellulose the abbreviated.
  • the nuclear particles obtained in the step (c) are coated to provide the nuclear particles having voids formed between the crystalline cellulose and the substantially spherical additive, and a coating layer covering the same.
  • Manufacturing method including. [19]
  • the compound has the following formula (Ia).
  • Method. [21] The production method according to any one of the above [18] to [20], wherein the step (e) is a step of tableting the granular preparation to obtain a vaginal tablet.
  • the pharmaceutical composition of the present invention which is a vaginal insert
  • a sufficient dose of the active ingredient of the present invention can be contained therein, and even in such a case, the above-mentioned compound which is an active ingredient is stably retained and also.
  • the active ingredient When inserted into the vagina, the active ingredient is well eluted. Due to these properties, the pharmaceutical composition of the present invention exhibits good bioabsorbability.
  • FIG. 1 is a diagram illustrating the internal structure of the granular pharmaceutical product contained in the pharmaceutical composition of the present invention.
  • the active ingredient and the needle-shaped and / or substantially columnar-shaped nuclear particle component 1 and the substantially spherical-shaped nuclear particle component 2 are included in the nuclear particles. This is the result of confirming the elution of the active ingredient from the vaginal tablet which is the pharmaceutical composition of the present invention. This is the result of confirming the elution of the active ingredient from the vaginal tablet which is the pharmaceutical composition of the present invention. This is the result of confirming the stability of the active ingredient in the vaginal tablet which is the pharmaceutical composition of the present invention. This is the result of confirming the stability of the active ingredient of the pharmaceutical composition of the present invention to a surfactant.
  • vaginal tablet which is the pharmaceutical composition of the present invention
  • vaginal tablet which is the pharmaceutical composition of the present invention
  • repeated administration of vaginal tablets which is the pharmaceutical composition of the present invention
  • rats and confirmation of transfer to plasma and tissues This is the result of administering the vaginal tablet, which is the pharmaceutical composition of the present invention, to humans and confirming the transfer into blood.
  • the pharmaceutical composition of the present invention can be used to treat or prevent a disease caused in the vagina or the peripheral part of the vagina by a pathogenic virus.
  • the pathogenic virus is a virus that causes a disease in or around the vagina, and examples thereof include human papillomavirus and herpes simplex virus.
  • intravaginal or peri-vaginal refers to the vagina, vaginal cavity and vagina, uterus, uterine body, endometrial and cervix, genital area (labia majora, labia minora, perineal lips, and urinary tract). It is used to include the mouth).
  • Diseases caused in the vagina or around the vagina are not limited to, for example, cervical cancer, diseases diagnosed as LSIL, ASC-US, ASC-H, or HSIL according to Bethesda classification, mild dysplasia uterus.
  • cervical intraepithelial neoplasia CIN1
  • CIN2 moderately dysmorphic cervical intraepithelial neoplasia
  • CIN3 highly dysplastic cervical intraepithelial neoplasia
  • condyloma apex and genital herpes.
  • the diagnosis of LSIL, ASC-US, ASC-H, or HSIL by Bethesda classification is made by vaginal cytopathology
  • the diagnosis of CIN1 to CIN3 is made by vaginal histology.
  • the active ingredient of the pharmaceutical composition of the present invention is the following general formula (I).
  • the active ingredient of the present invention exhibits antiviral activity against pathogenic viruses.
  • examples of the virus in which the active ingredient of the present invention exhibits antiviral activity include, but are not limited to, human papillomavirus and herpes simplex virus.
  • human papillomavirus HPV16, 18 and the like are known as causative viruses of cervical cancer, and HPV6, 11 and the like are known as causative viruses of condyloma acuminata. Shows viral activity (eg, Non-Patent References 1-4).
  • the pharmaceutical composition of the present invention may contain other drugs in addition to the above active ingredients.
  • other agents include antiviral agents, anti-inflammatory agents, antibacterial agents, antifungal agents and the like.
  • examples of the antiviral agent include acyclovir.
  • examples of the anti-inflammatory agent include non-steroidal anti-inflammatory drugs (NSAIDs).
  • examples of the antibacterial agent include metronidazole and clindamycin.
  • examples of the antifungal agent include fluconazole and itraconazole.
  • the amount of the active ingredient in the pharmaceutical composition of the present invention is not particularly limited as long as the pharmaceutical composition of the present invention exerts a desired effect, but in the treatment and / or prevention of diseases caused by human papillomavirus, for example.
  • the lower limit can be 10 mg, 20 mg, 30 mg, 40 mg, or 50 mg per tablet
  • the upper limit can be 1000 mg, 800 mg, 600 mg, 500 mg, 400 mg, 300 mg, 200 mg, or 100 mg, due to simple herpes.
  • the lower limit may be 2 mg, 5 mg, or 10 mg
  • the upper limit may be 200 mg, 100 mg, or 80 mg per tablet.
  • the pharmaceutical composition of the present invention comprises a nonionic surfactant.
  • a nonionic surfactant as long as it is pharmaceutically acceptable, and as long as it does not have a non-negligible effect on the stability and dissolution of the active ingredient contained in the pharmaceutical composition of the present invention.
  • examples thereof include alkyl polyoxyethylene ether, polyoxyethylene fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, polyglycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, and the like, and more preferably polysorbate. , More preferably polysorbate 80.
  • These surfactants may be used alone or in combination of two or more. In the process of producing the pharmaceutical composition of the present invention, these surfactants may be dissolved in, for example, water, alcohol or the like so as to be contained in the pharmaceutical composition of the present invention.
  • the amount of the nonionic surfactant in the pharmaceutical composition of the present invention is not particularly limited as long as the use as a vaginal insertion agent exhibiting antiviral activity, which is the object of the present invention, is not hindered, but the total amount of the pharmaceutical composition is not limited. It is contained in an amount of 1.5% by weight or more and less than 10% by weight. If the content of the surfactant is more than 10% by weight, the moldability and the granulation property are deteriorated, and it becomes difficult to produce it as a vaginal insert (a form of a vaginal tablet, a vaginal capsule, or a vaginal suppository). ..
  • the content of the surfactant is less than 1.5% by weight, the elution of the active ingredient from the pharmaceutical composition containing the target therapeutically effective amount of the active ingredient may be insufficient.
  • the content of the surfactant is determined in consideration of the amount of the active ingredient of the present invention contained in the pharmaceutical composition, but the lower limit is 1.5% by weight based on the total amount of the pharmaceutical composition.
  • the content of the surfactant is preferably 6 to 9% by weight, more preferably 7 to 9% by weight, still more preferably 7 to 8% by weight, based on the total amount of the pharmaceutical composition.
  • the amount of the nonionic surfactant with respect to the active ingredient of the present invention in the pharmaceutical composition of the present invention is not particularly limited as long as the object of the present invention is achieved, but is contained in an amount of 2 times or less the amount of the active ingredient. Is preferable. If the amount of the surfactant with respect to the active ingredient is 2 times or less, the active ingredient is stably stored and the decomposition products derived from the active ingredient can be ignored. Further, the lower limit of the amount of the surfactant with respect to the active ingredient is not particularly limited as long as the active ingredient is sufficiently eluted, and can be, for example, at least 0.4 times with respect to the active ingredient.
  • the surfactant has 0.4 times, 0.5 times, 0.6 times, 0.7 times, 0.8 times, and 0.9 times as the lower limit with respect to the active ingredient. , Or 1.0 times, with an upper limit of 2.0 times, 1.9 times, 1.8 times, 1.7 times, 1.6 times, 1.5 times, 1.4 times, or 1 . Contains 3 times the amount.
  • the content of the surfactant is preferably 1.0 to 1.7 times, more preferably 1.0 to 1.6 times, still more preferably 1.0 to 1.5 times, that of the active ingredient. , More preferably 1.0 to 1.4 times, and most preferably about 1.2 times.
  • the pharmaceutical composition of the present invention takes the form of a vaginal inserter inserted into the vagina.
  • the vaginal insert include vaginal tablets, vaginal capsules, vaginal suppositories, and vaginal tablets are preferable.
  • the vaginal insert which is the pharmaceutical composition of the present invention, includes a granular preparation comprising nuclear particles and a coating layer covering the nuclear particles.
  • Nuclear particles include said active ingredient, acicular and / or substantially columnar crystalline cellulose, pharmaceutically acceptable substantially spherical additives, and nonionic surfactants.
  • a granular preparation comprising the nuclear particles used in the present invention and a coating layer covering the nuclear particles (in the present specification, it may be referred to as "granular preparation used in the present invention” or “granular preparation of the present invention”.
  • the granular preparation can be made into a vaginal tablet by tableting or molding, can be encapsulated into a vaginal capsule, or can be made into a vaginal suppository by tableting or molding.
  • compression molding is preferable for molding, and compression encapsulation is preferable for encapsulation.
  • the acicular and / or substantially columnar crystalline cellulose contained in the pharmaceutical composition of the present invention (in the present specification, may be simply referred to as “needle crystalline cellulose”) has an acicular or substantially columnar shape.
  • the needle-shaped crystalline cellulose is a crystalline cellulose used as an additive in the preparation of a pharmaceutical preparation and has an needle-like or substantially columnar shape.
  • Needle-shaped crystalline cellulose can be contained in the granular preparation of the present invention contained in the composition.
  • the crystalline cellulose used as a raw material may be any as long as it can provide needle-shaped and / or substantially columnar crystals in a sufficient proportion to exert the effect of the present invention when the pharmaceutical composition of the present invention is prepared.
  • the proportion of needle-shaped and / or substantially columnar-shaped crystals is not particularly limited, but the total number of crystals (particles) is limited.
  • the lower limit is, for example, 60%, 65%, 70%, 75%, or 80%
  • the upper limit is, for example, 100%, 98%, or 95%.
  • the number of needle-shaped and / or substantially columnar-shaped crystals (particles) is preferably 60 to 100%, more preferably 70 to 100%, still more preferably 80 to 100% of the total.
  • the term "needle-shaped or substantially columnar crystalline cellulose" is remarkable in the longitudinal and horizontal lengths in the longitudinal cross section of the crystalline cellulose on the image (the shape transferred to the plane) measured by an electron microscope. Crystalline cellulose with a difference.
  • the remarkable difference in the vertical and horizontal lengths can be expressed by, for example, the aspect ratio.
  • the aspect ratio of the crystalline cellulose is not particularly limited as long as the effect of the present invention is exhibited, but the lower limit is, for example, preferably 1.8, more preferably 2.2, and even more preferably 2.5.
  • the upper limit value can be, for example, 10, 9, or 8.
  • the range of the average aspect ratio of the needle-shaped crystalline cellulose is not particularly limited, but is preferably 1.8 to 10, more preferably 2.2 to 10, and even more preferably 2.5 to 10.
  • the present invention has an average aspect ratio of crystals in the range of 1.7 to 10, particularly 2.0 to 10. It is suitably used in the production of the pharmaceutical composition of.
  • the diameter of the particles contained in the crystalline cellulose raw material for providing the needle-shaped crystalline cellulose is not particularly limited as long as the effect of the present invention is exhibited, but the average particle diameter (D50) is preferably 50 to 200 ⁇ m, more preferably 60. It is ⁇ 150 ⁇ m, more preferably 70-100 ⁇ m.
  • the particle size and average particle size of the particles are determined by, for example, a laser diffraction method (measurement method: dry method, scattering intensity: 1% or more, light scattering model: Mie) using a commercially available particle size distribution meter (for example, Mastersizer3000, manufactured by Spectris). It is measured by the scattering theory).
  • the content of the crystalline cellulose raw material for providing needle-shaped crystalline cellulose with respect to the entire pharmaceutical composition is not particularly limited as long as the effect of the present invention is exhibited, but it is preferable as a lower limit with respect to the total mass of the pharmaceutical composition. 2% by weight, more preferably 3% by weight, still more preferably 5% by weight, while the upper limit is preferably 30% by weight, more preferably 20% by weight, but needle-like crystals in the crystalline cellulose raw material. It is appropriately selected depending on the content of cellulose, the type and amount of other additives added to the pharmaceutical composition, and the desired properties of the desired pharmaceutical composition.
  • the content of the crystalline cellulose raw material for providing the needle-shaped crystalline cellulose with respect to the granular preparation contained in the pharmaceutical composition is not particularly limited as long as the effect of the present invention is exhibited, but is the lower limit with respect to the total mass of the granular preparation.
  • the content is preferably 5% by weight, more preferably 10% by weight, and the upper limit is preferably 50% by weight, more preferably 40% by weight, but contains needle-like crystalline cellulose in the crystalline cellulose raw material. It is appropriately selected depending on the amount, the type and amount of other additives to be added, and the desired properties of the desired pharmaceutical composition.
  • the pharmaceutically acceptable substantially spherical additive used in the pharmaceutical composition of the present invention (in the present specification, may be referred to as "substantially spherical additive”) is an additive that can be used in the field of pharmaceuticals. And it is a substantially spherical one.
  • the substantially spherical particle means that particles having a substantially spherical shape are mainly contained as a component, and for example, the substantially spherical particles account for 80% or more, preferably 85 of the total. It means an additive contained in% or more, more preferably 90% or more, still more preferably 95% or more, and most preferably almost 100%.
  • substantially spherical means a shape in which there is no significant difference in vertical and horizontal lengths on an image (a shape transferred to a plane) measured by an electron microscope. Therefore, in the present specification, “substantially spherical” is used in the sense of including an ellipsoidal shape, a polyhedral shape (including a cubic shape), and a polyhedral shape with rounded corners, in addition to a shape close to a spherical shape.
  • the "substantially spherical” does not necessarily mean that the image measured by the electron microscope is a spherical shape itself, for example, a distorted spherical shape, an ellipsoidal shape, a polyhedral shape (including a cubic shape), or a polyhedral shape with rounded corners. May be.
  • the average aspect ratio of the substantially spherical additive in the nuclear particles contained in the pharmaceutical composition of the present invention is preferably 1.0 to 1.6, more preferably 1.0 to 1.5, and further. It is preferably 1.0 to 1.3, and even more preferably 1.0 to 1.2.
  • the diameter of the particles contained in the raw material for providing the substantially spherical additive in the nuclear particles contained in the pharmaceutical composition of the present invention is not particularly limited as long as the effect of the present invention is exhibited, but the average particle diameter (D50). Is preferably 1 to 300 ⁇ m, more preferably 5 to 200 ⁇ m, and even more preferably 10 to 150 ⁇ m.
  • the particle size and average particle size of the particles are determined by, for example, a laser diffraction method (measurement method: dry method, scattering intensity: 1% or more, light scattering model: Mie) using a commercially available particle size distribution meter (for example, Mastersizer3000, manufactured by Spectris). It is measured by the scattering theory).
  • the granular preparation contained in the pharmaceutical composition of the present invention contains the substantially spherical additive.
  • the content of the substantially spherical additive in the entire pharmaceutical composition is not particularly limited as long as the effects of the present invention are exhibited, but the lower limit is preferably 10% by weight, based on the total mass of the pharmaceutical composition.
  • the upper limit is preferably 15% by weight, preferably 50% by weight, more preferably 40% by weight, but the type and amount of other additives added to the pharmaceutical composition, the desired pharmaceutical composition. It is appropriately selected according to the desired characteristics of the object.
  • the content of the substantially spherical additive to the granular preparation contained in the pharmaceutical composition is preferably 30% by weight, more preferably 35% by weight, as a lower limit with respect to the total mass of the granular preparation.
  • the upper limit is preferably 90% by mass, more preferably 80% by weight, but is appropriately selected depending on the type and amount of other additives to be added and the desired properties of the desired pharmaceutical composition. ..
  • the substantially spherical additive may be used alone or in combination of two or more components, but preferably a combination of two or more components having different average particle sizes. Is.
  • the average particle size of each component is different.
  • the lower limit of the ratio of the average particle diameters of the two different components is not particularly limited, and examples thereof include 1.2, 1.3, 1.4, 1.5, or 2, and the upper limit thereof.
  • the value is not particularly limited, and examples thereof include 20, 15, 10, 5, 4, or 3.
  • the ratio of the average particle size of the two different components is not particularly limited, but is, for example, 1.2 to 20, preferably 1.3 to 10, more preferably 1.5 to 5, and even more preferably 2 to 3. ..
  • the substantially spherical additive is not particularly limited as long as it is a pharmaceutically acceptable additive, and examples thereof include excipients, binders, disintegrants, lubricants, and the like, and the effects of the present invention can be achieved. These additives can be used without limitation as long as they can be used.
  • an additive classified as an excipient is used as the substantially spherical additive in the present invention. Specific examples thereof include, but are not limited to, sugars (including sugars, sugar hydrates, sugar alcohols, etc.), inorganic compounds, and the like.
  • the sugar is not particularly limited, and examples thereof include monosaccharides such as glucose, disaccharides such as lactose and sucrose, and polysaccharides such as starch and cellulose.
  • examples of starch include potato starch, wheat starch, corn starch, rice starch and the like.
  • corn starch is preferably used.
  • the sugar hydrate is not particularly limited, and examples thereof include any hydrate of the above-mentioned sugar, and lactose hydrate is preferably used.
  • the sugar alcohol is not particularly limited, and examples thereof include sugar alcohols derived from any sugar, and mannitol or sorbitol is preferably used.
  • the inorganic compound is not particularly limited, and examples thereof include phosphates such as anhydrous calcium phosphate.
  • Preferred examples of the substantially spherical additive include disaccharides such as lactose, lactose hydrate and sucrose, corn starch and potato starch.
  • the “aspect ratio” means the value (major axis / minor axis) of the ratio of the major axis to the minor axis of the particles contained in the component in the particle image analysis using an electronic microscope, and also "average”.
  • “Aspect ratio” is the aspect ratio of 10 or more particles selected arbitrarily, and the aspect ratio of the remaining particles excluding the aspect ratio values of the upper 10% and lower 10% of the aspect ratio values. Means the average value of.
  • the total mass of the crystalline cellulose raw material for providing needle-shaped crystalline cellulose and the substantially spherical additive is not particularly limited as long as the effect of the present invention is exhibited, but as a lower limit with respect to the total mass of the pharmaceutical composition, for example, It is 10% by weight, 20% by weight, 25% by weight, or 30% by weight, while the upper limit is, for example, 90% by weight, 80% by weight, 70% by weight, or 60% by weight, preferably 20 to 80% by weight. It is% by weight, more preferably 30 to 70% by weight.
  • the ratio of the substantially spherical additive to the crystalline cellulose raw material for providing needle-shaped crystalline cellulose is not particularly limited as long as the effect of the present invention is exhibited. For example, it is 1 to 10 times, preferably 2 to 5 times.
  • the coating layer can coat the nuclear particles and prevent the surfactant or drug contained in the nuclear particles from leaking to the surface of the granular preparation of the present invention.
  • the coating layer can suppress the leakage of the surfactant by the coating layer, the aggregation of the granular preparation can be suppressed, the decrease in fluidity can be suppressed, and the vaginal tablet can be satisfactorily produced.
  • the components constituting the coating layer are not particularly limited, and examples thereof include a water-soluble coating agent.
  • a water-soluble coating agent one type may be used alone, or two or more types may be used in combination.
  • the water-soluble coating agent preferably comprises at least one component selected from polyalkylene glycols and polysaccharides or derivatives thereof.
  • the polysaccharide or its derivative is preferably a cellulose derivative, and examples thereof include methyl cellulose, hydroxymethyl cellulose, and hydroxypropyl methyl cellulose.
  • a cellulose derivative examples thereof include methyl cellulose, hydroxymethyl cellulose, and hydroxypropyl methyl cellulose.
  • the cellulose derivative one type may be used alone, or two or more types may be used in combination.
  • the polyalkylene glycol examples include polyethylene glycol and the like.
  • the coating agent may be used in combination with a plasticizer.
  • Plasticizers include acetyltributyl citrate, acetyltriethyl citrate, castor oil, diacetylated monoglyceride, dibutyl sevacinate, sorbitol, dextrin, diethyl phthalate, glycerin, polyalkylene glycol, polyethylene glycol monoethyl ether, propylene glycol, and scent. Examples thereof include benzyl acid acid, purified water, sorbitol sorbitan solution, triacetin, tributyl citrate, triethyl citrate, chlorobutanol and the like. Of these plasticizers, polyalkylene glycol is preferably used, and polyethylene glycol (macrogol) is more preferable. These plasticizers may be used alone or in combination of two or more.
  • the components constituting the coating layer may be used as they are, or may be dissolved in water, alcohol, etc., if necessary.
  • the amount of the coating layer in the pharmaceutical composition of the present invention is not particularly limited as long as the granular preparation and the pharmaceutical composition of the present invention exert a desired effect, but the ratio to the total mass of the nuclear particles to be coated (mass ratio: coating layer).
  • the lower limit is, for example, 0.001, 0.002, 0.003 or 0.005, and the upper limit is, for example, 0.1, 0.05, 0.03. , Or 0.02, preferably 0.002 to 0.05, more preferably 0.005 to 0.05, and even more preferably 0.005 to 0.02.
  • the ratio of the amount of the components constituting the coating layer has a lower limit of, for example, 0.0003. It is 0.001 or 0.002, and the upper limit is, for example, 0.05, 0.03, 0.02, or 0.01, and the ratio is preferably 0.001 to 0.03. It is preferably 0.001 to 0.02, more preferably 0.002 to 0.01.
  • the particle size of the granular preparation of the present invention is not particularly limited, and the lower limit is, for example, 50 ⁇ m, 60 ⁇ m, 80 ⁇ m, or 100 ⁇ m, and the upper limit is, for example, 700 ⁇ m, 500 ⁇ m, 400 ⁇ m, or 300 ⁇ m.
  • the average particle size (D50) is, for example, 100 to 400 ⁇ m, preferably 100 to 300 ⁇ m, and more preferably 120 to 250 ⁇ m.
  • the average particle size of the granular preparation can be measured by the same method as the above-mentioned measuring method.
  • the pharmaceutical composition of the present invention includes a coating layer that covers the nuclear particles in the granular preparation contained therein, leakage of the surfactant or drug (active ingredient) contained in the nuclear particles from the granular preparation.
  • the aggregation of the granular preparation can be suppressed, and it can be formulated as a vaginal insert.
  • molding especially compression molding, is possible when producing vaginal tablets and vaginal suppositories, and vaginal capsules can be used.
  • vaginal capsules include hard capsules.
  • the pharmaceutical composition of the present invention many voids are formed between the needle-like crystalline cellulose and the substantially spherical additive in the nuclear particles in the granular preparation.
  • FIG. 1 schematically shows the situation. Therefore, the nuclear particles can have many voids, that is, a good porosity, and the nonionic surfactant and the active ingredient of the present invention can enter the voids.
  • a pharmaceutical composition containing a larger amount of the active ingredient of the present invention and a nonionic surfactant is provided.
  • the pharmaceutical composition of the present invention since a larger amount of the active ingredient and the nonionic surfactant are retained, good transfer to the vaginal peripheral tissue when administered intravaginally. You can achieve sex. This is supported by the fact that it is transferred to the blood.
  • the pharmaceutical composition of the present invention contains, as long as it does not interfere with the effects of the present invention, pharmaceutically acceptable additives different from the above-mentioned components contained in the nuclear particles and the components constituting the coating layer covering the same. You may be.
  • Additives include, for example, excipients, disintegrants, mold release agents, separators, lubricants, binders, fluidizers, stabilizers, adsorbents, brighteners, wetting agents, wetting modifiers, fillings. Examples thereof include agents, pressure-sensitive agents, thickeners, moisture-proofing agents, sweeteners, flavors, and coloring agents.
  • These additives may have one component having two or more functions. In addition, these additives may be used alone or in combination of two or more.
  • the pharmaceutical composition of the present invention can be produced by the following steps.
  • Step a A step of mixing a nuclear particle raw material containing acicular and / or substantially columnar crystalline cellulose and a pharmaceutically acceptable substantially spherical additive to obtain a nuclear particle mixture.
  • Step b A step of dissolving or suspending the following compound in a mixture of a nonionic surfactant and a solvent to obtain a mixed solution.
  • [W represents S or O in the formula]
  • Step c The compound, the acicular and / or substantially columnar crystalline cellulose, said, were brought into contact with the nuclear particle mixture obtained in step (a) and the mixed solution obtained in step (b).
  • Step d Granules comprising the nuclear particles obtained in the step (c) and a coating layer covering the nuclear particles having voids formed between the crystalline cellulose and the additive.
  • Step of obtaining the preparation, and step e A step of processing the obtained granular preparation to obtain a vaginal insert in any form of a vaginal tablet, a vaginal suppository or a vaginal capsule.
  • the needle-shaped and / or substantially columnar-shaped crystalline cellulose that can be used in the step (a)
  • those described for the pharmaceutical composition can be used.
  • Various crystalline celluloses have been reported or commercially available as additives that can be added to pharmaceutical compositions, and among these, those mainly containing needle-shaped and / or substantially columnar-shaped crystals can be used without limitation.
  • the proportion of needle-like and / or substantially columnar-shaped crystals has a lower limit of, for example, 60%, 65%, 70%, 75%, or 80% with respect to the total number of crystals (particles). Yes, the upper limit is, for example, 100%, 98%, or 95%.
  • the number of needle-shaped and / or substantially columnar-shaped crystals (particles) is preferably 60 to 100%, more preferably 70 to 100%, still more preferably 80 to 100% of the total.
  • the crystalline cellulose containing many needle-shaped and / or substantially columnar-shaped crystals is not limited to this, and is, for example, among the crystalline celluloses that can be added to pharmaceutical products such as Theoras (registered trademark) (manufactured by Asahi Kasei Corporation). Examples thereof include products containing a large amount of needle-shaped and / or substantially columnar-shaped crystals.
  • the pharmaceutically acceptable substantially spherical additive that can be used in the step (a)
  • the one described for the pharmaceutical composition can be used.
  • examples include, but are not limited to, disaccharides such as lactose, lactose hydrate and sucrose, corn demp and potato starch.
  • the nonionic surfactant that can be used in the step (b) the one described for the pharmaceutical composition can be used.
  • polysorbate particularly polysorbate 80, can be mentioned.
  • the solvent that can be used in the step (b) is a solvent for dissolving or suspending a poorly water-soluble substance that can be used for producing a pharmaceutical composition, and the above compound can be sufficiently dissolved or suspended.
  • the solvent is preferably an organic solvent.
  • the solvent added in the manufacturing process (particularly, the organic solvent) volatilizes in the drying step, and therefore can be used without particular limitation as long as the residual substance does not pose a problem.
  • methanol, ethanol, ethyl acetate, acetone, diethyl ether and the like can be mentioned, preferably methanol, ethanol, or ethyl acetate, and particularly preferably methanol. Since these organic solvents are volatilized in the drying step in the production method of the present invention, they do not remain in the produced pharmaceutical composition, and the pharmaceutical composition of the present invention is a vaginal insertion agent that does not contain them. ..
  • dissolving or suspending a compound used in the present invention means a state in which all of the compounds are dissolved or suspended, and a state in which a part of the compound is dissolved and another part is suspended. It is also used in the sense of including.
  • the pharmaceutical composition of the present invention can be produced, for example, according to the following procedure. First, needle-shaped and / or substantially columnar crystalline cellulose and at least one pharmaceutically acceptable substantially spherical additive are added to a fluidized bed granulator (for example, FD-MP-01D, manufactured by Paulek Co., Ltd.). To obtain a nuclear particle mixture (primary particles).
  • a fluidized bed granulator for example, FD-MP-01D, manufactured by Paulek Co., Ltd.
  • the active ingredient of the present invention is added to a nonionic surfactant and stirred using a stirrer (for example, NZ-1200, manufactured by Tokyo Rika Kikai Co., Ltd.) to dissolve or suspend the active ingredient.
  • a stirrer for example, NZ-1200, manufactured by Tokyo Rika Kikai Co., Ltd.
  • the mixed solution drug solution
  • the obtained mixture and the mixed solution are brought into contact with each other using a fluidized bed granulator, and the mixed solution is adhered to the nuclear particles in the mixture to obtain nuclear particles.
  • the contact between the mixture and the mixture is carried out by, for example, a method of spraying the mixture on the mixture, a method of immersing the mixture in the mixture, or the like.
  • the nuclear particles are dried as necessary, and then the nuclear particles are coated with the components constituting the coating layer (coating layer component).
  • the coating of the nuclear particles is performed, for example, by a method of spraying the coating layer component on the nucleus, a method of immersing the nuclear particles in the coating layer component, or the like.
  • the particles having the nuclear particles and the coating layer covering the nuclear particles are dried to obtain the granular preparation of the present invention.
  • granules comprising a nuclear particle coated with the nuclear particle and having a void formed between the acicular crystalline cellulose and a substantially spherical additive and a coating layer covering the nuclear particle.
  • the term "obtaining a pharmaceutical product” means that, as described above, the coating layer component is sprayed on the nuclear particles, or the nuclear particles are immersed in the coating layer component and then dried, to obtain a granular product.
  • the granular preparation is formulated into a dosage form of a vaginal insert (vaginal tablet, vaginal suppository, or vaginal capsule). Molding into vaginal tablets can be performed, for example, by tableting molding.
  • the method for tableting the granular preparation of the present invention is not particularly limited, and a known method can be used.
  • the conditions for tableting are not particularly limited, and can be appropriately adjusted depending on the types of nuclear particle components, surfactants, drugs, coating layer components, and the like.
  • Examples of the method for tableting and molding the granular preparation include a method of locking the preparation using a locking machine such as a rotary type tableting machine and a single-shot type tableting machine.
  • the pharmaceutical product it is preferable to tablet-mold the pharmaceutical product using a rotary tableting machine.
  • the rotary lock press include VIRGO 0512SS2AY manufactured by Kikusui Seisakusho Co., Ltd.
  • the pharmaceutical composition in the form of a tablet contains a pharmaceutically acceptable additive in addition to the granular preparation of the present invention, the granular preparation of the present invention and the pharmaceutically acceptable additive are previously prepared. Tablet after mixing.
  • the method of mixing the granular preparation and the additive is not particularly limited, and a known method can be used.
  • the method of mixing the granular preparation and the additive include a method of mixing using a mixer such as a V-type mixer. Specifically, it can be mixed using a V-type mixer (TCV-20) manufactured by Tokuju Kosakusho Co., Ltd.
  • the method of using the granular preparation of the present invention as a capsule is not particularly limited, and a known method can be used. Specifically, it is produced by filling a capsule film made of gelatin, a plant-derived raw material, or the like with a granular preparation.
  • the filling of the capsule film is not particularly limited, and can be performed by a known method such as auger type powder filling, radish press type powder filling, and vibration type powder filling.
  • auger-type powder filling a pharmaceutical preparation of granules that is dropped and supplied from a hopper into a cap-shaped body that is usually formed of a gelatin film and has open ends is placed directly on the capsule body by the rotational pressure of a stirring blade and an auger. After quantitative filling, capsules can be produced by coaxially bonding the bodies.
  • the method of using the granular preparation of the present invention as a vaginal suppository is not particularly limited, and a known method can be used.
  • Bases for vaginal suppositories include, but are not limited to, cocoa butter, hard fats, macrogols such as PEG6000 (eg, macrogol 6000), or mixtures of glycerin-gelatin.
  • the suppository may further include a bioadhesive, eg, a mucosal adhesive, to promote the adhesion and long-term contact of the composition to the mucosa, eg, the vaginal epithelium.
  • Antiviral activity of the active ingredient of the present invention inhibits cyclin-dependent kinase (CDK) 9 and causes human papillomavirus or herpes simplex virus. It has been reported that it exhibits antiviral activity against viruses including herpes virus (for example, Non-Patent Document 1 has anti-human papillomavirus activity, Non-Patent Document 2 has anti-HBV activity, and Non-Patent Document 3 has anti-HIV activity. , Non-Patent Document 4 reports that it exhibits anti-human herpes simplex virus activity, anti-human cytomegalovirus activity and anti-human adenovirus activity).
  • CDK cyclin-dependent kinase
  • Hela S3 cells human cervical cancer cell line carrying the human papillomavirus type 18 genome were seeded on a plate, cultured for 24 hours, and then the above compound was added to a final concentration of 30 ⁇ M. After 3 days of culturing, cells were collected to obtain mRNA and cytolysate. Using the obtained mRNA as a template, real-time RT-PCR was performed using HPV18 E6 primer or GAPDH primer, and the induction factor of the E6 gene expression rate was calculated. As a result, it was confirmed that the above compound suppresses viral growth by reducing the expression of the E6 gene, that is, by suppressing the transcription of the E6 gene of human papillomavirus.
  • the cytolysate obtained above was developed by SDS-PAGE and Western blotting using an anti-p53 antibody was performed to evaluate the expression of p53. As a result, it was confirmed that the above compound significantly increased the expression level of p53. This indicates that the above compounds are effective in reducing viral proteins by their papillomavirus growth inhibitory activity, inhibiting the degradation of cell cycle proteins and, as a result, restoring normal cell function. There is.
  • a plaque assay confirmed a viral growth inhibitory effect on herpes simplex virus type 2 (HSV-2).
  • Vero cells African green monkey kidney cells
  • Vero cells were seeded on plates and incubated overnight. The day after cell seeding, HSV-2 was infected with Vero cells, a cell culture medium containing the above compound was added, and the cells were cultured for 24 hours. Then, a cell disruption solution was obtained. In order to measure the amount of HSV-2 contained in the obtained cell disruption solution, the obtained cell disruption solution was again infected with Vero cells for 1 hour and cultured in a cell culture medium containing ⁇ -globulin for 48 hours. bottom.
  • the above compound has an inhibitory effect on the growth of herpes simplex virus.
  • Example 2 Preparation of the pharmaceutical composition of the present invention
  • the granular preparation of the present invention was prepared according to the production process shown below.
  • Step 1 Preparation step of nuclear particle mixture
  • Needle-shaped and / or substantially columnar crystalline cellulose Needle-shaped and / or substantially columnar crystalline cellulose (Theoras UF-702, average particle size 90 ⁇ m, manufactured by Asahi Kasei Co., Ltd.) and a pharmaceutically acceptable substantially spherical additive (milk sugar hydrate (SuperTab®).
  • Step 2 Drug mixture preparation step
  • the active ingredient compound (IA) was dissolved or suspended in a mixture of a nonionic surfactant (polysorbate 80) and a solvent (ethanol) to obtain a drug mixture.
  • Step 3 Nuclear particle preparation step
  • the nuclear particle mixture (primary particles) obtained in step (1) is sprayed with the drug mixture obtained in step (2), and the drug solution adheres to the primary particles.
  • Got (Step 4: Final step of preparation of granular preparation) Using a fluidized bed granulator, the coated layer solution is sprayed on the nuclear particles obtained in step (3), dried at 60 ° C., and the granular preparation of the present invention in which the nuclear particles are coated with the coated layer solution is prepared. Obtained.
  • Step 5 Locking step
  • Additives excipients, fluidizing agents, excipients, and lubricants in arbitrary amounts
  • the obtained mixture was tableted to produce a vaginal tablet as a vaginal insert.
  • vaginal tablets for small animals Preparation of vaginal tablets for small animals
  • the pharmaceutical composition according to the formulation shown in the table below was produced as a vaginal tablet (1 tablet is a tablet of 80 mg) for a test using small animals.
  • vaginal tablets for human administration Preparation of vaginal tablets for human administration
  • the pharmaceutical composition according to the formulation shown in the table below was produced as a vaginal tablet (1 tablet is 800 mg) for administration to humans.
  • Example 3 Dissolution test of active ingredient in vaginal tablets Based on the formulation of the 50 mg tablet described in Example 2, the content of compound (IA) was 50 mg and the content of polysorbate 80 (PS80) was adjusted. , 20 mg (2.5% of the total amount of vaginal tablets), 40 mg (5.0% of the same), 60 mg (7.5% of the same), or 80 mg (10% of the same) of vaginal tablets (1 tablet) 800 mg tablets) were produced. Further, as a control, a vaginal tablet containing no polysorbate 80 was produced in the same manner.
  • PS80 polysorbate 80
  • vaginal tablet (1 tablet) having a polysorbate 80 (PS80) content of 60 mg and a compound (IA) content of 10 mg, 25 mg, or 50 mg, respectively. 800 mg tablets) were produced.
  • the test was carried out at 50 rpm by the paddle method using 700 mL of McIlvaine buffer (pH 4.0) diluted in the test solution according to the section of the dissolution test method of the Japanese Pharmacopoeia general test method. The results are shown in FIG. From the above results, it was confirmed that the compound was rapidly eluted by blending the polysorbate 80.
  • Example 4 Stability test of active ingredient in vaginal tablets Based on the formulation of the 50 mg tablet described in Example 2, the content of compound (IA) was 50 mg and the content of polysorbate 80 (PS80) was adjusted. , 20 mg (2.5% with respect to the total amount of vaginal tablets), 60 mg (7.5%), or 80 mg (10%), respectively, produced vaginal tablets (1 tablet is 800 mg).
  • the ratio of polysorbate to compound (IA) in each tablet was PS80 2.5% tablet (0.4 times), PS80 7.5% tablet (1.2 times), or PS80 10% tablet (1). .6 times).
  • Each tablet was stored at 60 ° C. and humidity for 3 weeks, and then the decomposition products were measured to examine the stability. The results are shown in FIG. In the figure, RRT0.6, RRT0.7, RRT2.4 or RRT2.8 indicate different decomposition products.
  • the content of polysorbate 80 was stable with a slight increase in decomposition products in each case.
  • Tablet B had significantly less related substances (decomposed products) than Tablet A.
  • Example 5 Administration test of vaginal tablets using rats
  • the vaginal tablets for small animals produced in Example 2 were vaginally administered to rats, and absorption (transition) into plasma, cervix and vaginal tissue was confirmed. ..
  • the test was planned and performed according to ethical standards for animal testing.
  • the rat was held by hand without anesthesia, and the vaginal tablet was placed in the deep part of the rat vagina (the part near the cervix) using a jig for intravaginal administration.
  • Vaginal tablets were administered once in the rat vagina and once daily for 5 days, and blood, cervix and vaginal tissues were collected and the concentration of compound (IA) in each tissue was analyzed.
  • Plasma, cervical tissue and vaginal tissue were collected from 3 animals in each group at 8 time points and stored at -80 ° C. Specifically, it was carried out as follows.
  • Influenza inhalation anesthesia was performed, the abdomen was opened, and blood was collected from the abdominal aorta. Plasma was stored at ⁇ 80 ° C. until the time of concentration measurement.
  • the blood was exsanguinated immediately after blood collection, and the entire uterus was removed from the vaginal tissue and washed with physiological saline from the uterine side. The excess part of the uterus and the vagina were cut off, the entire cervical tissue was washed again with physiological saline, the water was lightly wiped off, and then immediately frozen on dry ice and stored at -80 ° C.
  • the uterine tissue was cut, the vaginal opening of the remaining vagina was cut off, washed with physiological saline, lightly wiped off the water, immediately frozen on dry ice, and stored at -80 ° C.
  • Each of the extracted frozen tissues was added with 5 times the amount of physiological saline and pulverized with a bead crusher using a metal crusher to prepare a homogenate.
  • the prepared homogenate was stored at ⁇ 80 ° C. until the concentration was measured.
  • Example 6 Intravaginal administration test of vaginal tablets to humans
  • the vaginal tablets for humans (10 mg and 25 mg tablets) produced in Example 2 were used for administration to humans.
  • Entered EDTA before administration 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, and 7 days after administration.
  • Blood was collected by a vacuum blood collection tube and plasma was separated. The drug concentration in the separated plasma was measured by the LC / MS / MS method. The results are shown in FIG.
  • C max is the maximum blood concentration of each subject
  • T max is the time when the maximum blood concentration is reached
  • AUC 0- Day 8 is blood from before administration (0 hours of Day 1) to 7 days after administration (Day 8).
  • the mean value and standard deviation for each dose group were calculated from the change in medium concentration by the trapezoidal method. The results are shown below.
  • the vaginal tablet of the present invention has the transferability of the active ingredient into blood.
  • the active ingredient was transferred to the vaginal tissue such as the vagina and cervix, which is the administration site and the target tissue, and then the blood. It was thought to move into. Therefore, as in Example 5, when the vaginal tablet of the present invention was intravaginally administered to humans, transferability to blood was observed, and excellent transfer to cervical and vaginal tissues was confirmed.
  • the pharmaceutical composition of the present invention is useful for the prevention and / or treatment of viral intravaginal or peripheral vaginal diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/JP2021/006418 2020-10-28 2021-02-19 ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物 Ceased WO2022091442A1 (ja)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US18/033,584 US20230398107A1 (en) 2020-10-28 2021-02-19 Pharmaceutical composition for preventing or treating viral perivaginal disease
ES21885567T ES3045576T3 (en) 2020-10-28 2021-02-19 Pharmaceutical composition for preventing or treating viral perivaginal disease
CA3199945A CA3199945A1 (en) 2020-10-28 2021-02-19 Pharmaceutical composition for preventing or treating viral perivaginal disease
KR1020237014225A KR20230098175A (ko) 2020-10-28 2021-02-19 바이러스성 질 주변부 질환의 예방 또는 치료를 위한 의약 조성물
CN202180045812.6A CN115734782A (zh) 2020-10-28 2021-02-19 用于预防或治疗病毒性阴道周边部疾病的医药组合物
JP2022558836A JP7606239B2 (ja) 2020-10-28 2021-02-19 ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物
EP21885567.4A EP4238565B1 (en) 2020-10-28 2021-02-19 Pharmaceutical composition for preventing or treating viral perivaginal disease
PL21885567.4T PL4238565T3 (pl) 2020-10-28 2021-02-19 Kompozycja farmaceutyczna do zapobiegania lub leczenia wirusowej choroby okolic pochwy
ZA2023/04812A ZA202304812B (en) 2020-10-28 2023-04-26 Pharmaceutical composition for preventing or treating viral perivaginal disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-180339 2020-10-28
JP2020180339 2020-10-28

Publications (1)

Publication Number Publication Date
WO2022091442A1 true WO2022091442A1 (ja) 2022-05-05

Family

ID=81382191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/006418 Ceased WO2022091442A1 (ja) 2020-10-28 2021-02-19 ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物

Country Status (11)

Country Link
US (1) US20230398107A1 (https=)
EP (1) EP4238565B1 (https=)
JP (1) JP7606239B2 (https=)
KR (1) KR20230098175A (https=)
CN (1) CN115734782A (https=)
CA (1) CA3199945A1 (https=)
ES (1) ES3045576T3 (https=)
PL (1) PL4238565T3 (https=)
TW (1) TWI890738B (https=)
WO (1) WO2022091442A1 (https=)
ZA (1) ZA202304812B (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63275519A (ja) * 1987-05-06 1988-11-14 Taisho Pharmaceut Co Ltd 難溶性薬物含有顆粒の製造方法
JP2003508386A (ja) 1999-08-30 2003-03-04 シエーリング アクチエンゲゼルシャフト 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP2007517062A (ja) 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング
WO2009020198A1 (ja) * 2007-08-03 2009-02-12 Kinopharma, Inc. 抗ｄｎａウイルス作用を有するアニリン誘導体
WO2020218517A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法
WO2020218518A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010189337A (ja) * 2009-02-19 2010-09-02 Asahi Breweries Ltd 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法
JP6138635B2 (ja) * 2013-08-30 2017-05-31 旭化成株式会社 セルロース系核粒子及びその製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63275519A (ja) * 1987-05-06 1988-11-14 Taisho Pharmaceut Co Ltd 難溶性薬物含有顆粒の製造方法
JP2003508386A (ja) 1999-08-30 2003-03-04 シエーリング アクチエンゲゼルシャフト 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP2007517062A (ja) 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング
WO2009020198A1 (ja) * 2007-08-03 2009-02-12 Kinopharma, Inc. 抗ｄｎａウイルス作用を有するアニリン誘導体
WO2020218517A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法
WO2020218518A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AJIRO MASAHIKO, SAKAI HIROYUKI, ONOGI HIROSHI, YAMAMOTO MAKOTO, SUMI ERIKO, SAWADA TERUO, NOMURA TAKASHI, KABASHIMA KENJI, HOSOYA : "CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 24, no. 18, 15 September 2018 (2018-09-15), US, pages 4518 - 4528, XP055938710, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-17-3119 *
AJIRO, CLIN CANCER RES., vol. 24, no. 18, 30 April 2018 (2018-04-30), pages 4518 - 4528
OKAMOTO MIKA, HIDAKA AKEMI, TOYAMA MASAAKI, HOSOYA TAKAMITSU, YAMAMOTO MAKOTO, HAGIWARA MASATOSHI, BABA MASANORI: "Selective inhibition of HIV-1 replication by the CDK9 inhibitor FIT-039", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 123, 1 November 2015 (2015-11-01), NL , pages 1 - 4, XP055938712, ISSN: 0166-3542, DOI: 10.1016/j.antiviral.2015.08.012 *
OKAMOTO, ANTIVIRAL RES, vol. 123, 21 August 2015 (2015-08-21), pages 1 - 4
See also references of EP4238565A4
TANAKA, ANTIVIRAL RES., vol. 133, 8 August 2016 (2016-08-08), pages 156 - 64
YAMAMOTO, J CLIN INVEST., vol. 124, no. 8, 8 July 2014 (2014-07-08), pages 3479 - 88

Also Published As

Publication number Publication date
JP7606239B2 (ja) 2024-12-25
KR20230098175A (ko) 2023-07-03
EP4238565C0 (en) 2025-09-24
PL4238565T3 (pl) 2025-12-22
ES3045576T3 (en) 2025-11-28
EP4238565A4 (en) 2024-10-09
CA3199945A1 (en) 2022-05-05
EP4238565A1 (en) 2023-09-06
JPWO2022091442A1 (https=) 2022-05-05
EP4238565B1 (en) 2025-09-24
TW202216142A (zh) 2022-05-01
TWI890738B (zh) 2025-07-21
US20230398107A1 (en) 2023-12-14
ZA202304812B (en) 2024-08-28
CN115734782A (zh) 2023-03-03

Similar Documents

Publication Publication Date Title
US10251884B2 (en) Treatment of cancer and benign proliferative disorders
CN101422585A (zh) 含有莪术油的药物组合物的制药用途
EP3424512B1 (en) Uses of alginic acid sulfate in preparation of drugs and health care products for preventing and treating diseases caused by human papilloma viruses
EA024609B1 (ru) Лечение боли, обусловленной дислокацией базального слоя эндометрия
US20240148729A1 (en) Lopinavir and ritonavir for the treatment of cervix disorders
CN102670588A (zh) 鞣花酸用于制备抗病毒药物的应用
ROY et al. Vaginal condylomata: A human papillomavirus infection
JP2021525263A (ja) 処置
JP2010517992A (ja) 子宮内膜症の治療用の薬剤
CN103599093B (zh) 一种抗hpv药物制剂及用途
JP7606239B2 (ja) ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物
CN118340762B (zh) 柚皮素在制备治疗子宫肌瘤或子宫肉瘤药物方面的应用
HK40083240A (en) Pharmaceutical composition for preventing or treating viral perivaginal disease
RU2318510C1 (ru) Суппозитории вагинальные на основе 3,3`-дииндолилметана (метиндола)
WO2010150098A2 (en) Treatment of endometriosis
WO2020077819A1 (zh) 白头翁皂苷b4抗急性痛风性关节炎的医药用途
WO2020088364A1 (zh) 一种用于抗病毒感染的药物组合物及制备方法
WO2025160227A1 (en) Advantageous compounds for treatment of hpv infection and hpv-induced neoplasia
WO2019104587A1 (zh) 一种药物组合物及其用途
WO2025147598A1 (en) Device system and use for hpv infection and cervical intraepithelial neoplasia
Tay et al. The effects of oral contraceptive steroids, menopause and hormone replacement therapy on the cervical epithelium
HK1243360B (zh) 用於治疗子宫颈非典型性增生或子宫颈癌的包含亚硒酸盐或含亚硒酸盐化合物的药物制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21885567

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022558836

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3199945

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202347030075

Country of ref document: IN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023007654

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021885567

Country of ref document: EP

Effective date: 20230530

ENP Entry into the national phase

Ref document number: 112023007654

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230424

WWG Wipo information: grant in national office

Ref document number: 2021885567

Country of ref document: EP